Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV-C in Myasthenia Gravis Exacerbations
NCT02413580Phase 3Completed
- Sponsor
- Grifols
- Start
- Mar 2015
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in myasthenia gravis (MG), sponsored by Grifols. Started Mar 2015; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT02413580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413580.